Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. and certain senior officers for alleged violations of the Securities Exchange Act of 1934, specifically regarding misrepresentations about the company's revenue generation capabilities as an AI firm [1][3]. Group 1: Legal Action Details - The complaint was filed in the United States District Court for the Eastern District of Illinois on behalf of investors who purchased Tempus common stock between August 6, 2024, and May 27, 2025 [1]. - Investors are encouraged to join the class action lawsuit and can contact the Investor Relations Manager for more information [3][4]. Group 2: Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - Tempus AI, Inc. is facing a securities class action lawsuit for failing to disclose material information during the class period, which has led to a significant drop in its stock price [3][5]. Group 1: Lawsuit Details - Investors have until August 12, 2025, to file lead plaintiff applications if they purchased shares between August 6, 2024, and May 27, 2025 [1]. - The lawsuit is pending in the United States District Court for the Northern District of Illinois [1]. - The case is identified as Shouse v. Tempus AI, Inc., et al., No. 25-cv-06534 [5]. Group 2: Allegations Against Tempus - Tempus and its executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. - Spruce Point Capital Management reported several issues, including overstated AI capabilities, a history of executives cashing out before losses, and aggressive accounting practices [4]. - Concerns were raised regarding the AstraZeneca and Pathos AI deal, as well as a recent revision in financial guidance indicating weaknesses in core operations [4]. Group 3: Market Reaction - Following the news of the lawsuit and allegations, Tempus' share price fell by $12.67, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [5].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tempus securit ...

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank Group Corporation was compromised, creating the appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report by Spruce Point Capital Management raised significant concerns regarding Tempus AI's management, operations, and financial reporting [4]. - Following the release of this report, Tempus AI's stock price fell by more than 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff represents the interests of all class members and can select a law firm of their choice for litigation [5]. - Participation as lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [5].

Core Viewpoint - A securities class action lawsuit has been filed against Tempus AI, Inc. for failing to disclose material information, with a deadline for lead plaintiff applications set for August 12, 2025 [1][3]. Company Overview - Tempus AI, Inc. is facing allegations related to violations of federal securities laws during the class period from August 6, 2024, to May 27, 2025 [1][3]. Legal Context - The lawsuit is currently pending in the United States District Court for the Northern District of Illinois, with the case titled Shouse v. Tempus AI, Inc., et al., No. 25-cv-06534 [1][5]. Allegations - The allegations against Tempus include: - CEO Eric Lefkofsky and associates have a history of cashing out before public shareholders incur losses [4]. - The company's AI capabilities are claimed to be overstated [4]. - Board members and executives have connections to companies with restated financial results [4]. - Signs of aggressive accounting and financial reporting practices are present [4]. - Issues with the AstraZeneca and Pathos AI deal warrant scrutiny [4]. - Recent financial guidance revisions indicate weaknesses in core operations [4]. Market Reaction - Following the news of the lawsuit and allegations, Tempus' share price dropped by $12.67, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [5]. Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case, with a strong track record in recovering investment losses due to corporate fraud [5].

Core Viewpoint - A securities class action lawsuit has been filed against Tempus AI, Inc. for alleged misrepresentations and failures to disclose critical information regarding its financial practices and operations during the specified class period [1][2]. Allegations of Misconduct - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to artificially inflate revenue [2] - The business model of Tempus-acquired Ambry is alleged to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement, raising further concerns about the company's financial integrity [2] - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Impact of External Reports - A report from Spruce Point Capital Management highlighted numerous red flags regarding Tempus' management and financial reporting, including a history of executives cashing out before public shareholders incur losses [3] - The report also criticized the overstated AI capabilities of Tempus and pointed out aggressive accounting practices [3] - Concerns were raised about the AstraZeneca and Pathos AI deal, which warranted further scrutiny [3] - The company's recent financial guidance was seen as indicative of weaknesses in its core operations [3]. Stock Price Reaction - Following the release of the report and the ensuing allegations, Tempus' stock price dropped by $12.67 per share, or 19.23%, from $65.87 on May 27, 2025, to $53.20 on May 28, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations during the class period from August 6, 2024, to May 27, 2025 [1]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is described as aggressive and potentially unethical, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - These issues indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, a report by Spruce Point Capital Management highlighted numerous red flags regarding Tempus' management, operations, and financial reporting [4]. - The report criticized the company's actual AI capabilities as being overstated and pointed out a history of executives associated with troubled companies [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Impact - Following the release of a report by Spruce Point Capital Management that highlighted various red flags regarding Tempus' management and operations, the stock price fell by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [3][4]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action against Tempus AI, with options to serve as lead plaintiff or remain an absent class member [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged securities fraud, claiming the company misrepresented its AI capabilities and financial health to investors [1][4][5]. Company Overview - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM and has been accused of branding itself as an AI company despite limited revenue generation from AI solutions [4]. - The company primarily generates revenue through acquisitions, genomic testing, and data licensing agreements [4]. Allegations and Concerns - The lawsuit alleges that Tempus misled investors about the security and expansion of its data licensing agreements, particularly with AstraZeneca, and claimed high revenue potential from its acquisition of Ambry Genetics [4]. - A report by Spruce Point Capital Management raised concerns about Tempus' management practices, overstated AI capabilities, and aggressive accounting [5]. - Specific issues highlighted include the CEO's history of cashing out before public shareholders incur losses, connections to troubled companies, and recent revisions in financial guidance indicating weaknesses in core operations [5]. Financial Impact - Following the release of the Spruce Point Report, Tempus' stock price dropped by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [6]. Legal Information - Investors who purchased Tempus stock between August 6, 2024, and May 27, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by August 12, 2025 [6]. Legal Representation - Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for consumers affected by securities fraud [7].

Core Insights - Tempus AI is focusing on expanding partnerships with existing customers to drive growth, highlighted by a recent collaboration with AstraZeneca and Pathos Inc. to create a multimodal oncology foundation model [1][2][9] - The total remaining contract value for Tempus AI has exceeded $1 billion as of April 2025, indicating strong demand for its services [2][9] - Tempus AI is also enhancing its partnership with Illumina to integrate molecular profiling into standard care across various disease areas, which is expected to improve precision medicine accessibility [3][4][9] Partnership Developments - The collaboration with AstraZeneca involves a three-year, $200 million agreement aimed at leveraging over 300 petabytes of healthcare data to enhance clinical success rates in drug development [1][2] - Tempus AI's partnership with Illumina aims to address gaps in molecular profiling, enhancing AI-driven molecular analysis technologies to support comprehensive genomic profiling beyond cancer [3][4] - The company has also strengthened its relationship with Personalis to offer their minimal residual disease product, expanding market access for both companies [5] Financial Performance - Tempus AI shares have increased by 77% over the past year, outperforming the industry growth of 39.7% [6] - The company's valuation is stretched, with a forward five-year Price-to-Sales ratio of 8.85X compared to the industry average of 6.34X, indicating potential overvaluation concerns [7] Earnings Estimates - Current earnings estimates for Tempus AI show a projected loss of $0.21 for the current quarter and $0.62 for the current year, with slight improvements expected in the following year [11]